News

Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with ADHD Through a Video Game

  • BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital therapeutics company, today announced U.S. Food and Drug Administration (FDA) clearance of EndeavorOTCⓇ (AKL-T01) as an over-the-counter treatment for adults with attention-deficit/hyperactivity disorder (ADHD). Delivered through an engaging video game experience, EndeavorOTC is indicated to improve attention function as measured by computer-based testing in men and women with primarily inattentive or combined-type ADHD, who.
    06/18/2024

AKILI INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akili, Inc. - AKLI

  • NEW ORLEANS , June 14, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
    06/14/2024
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Akili, Inc. (AKLI) can hold. Click on Rating Page for detail.

The price of Akili, Inc. (AKLI) is 0.4331 and it was updated on 2025-01-14 07:01:43.

Currently Akili, Inc. (AKLI) is in undervalued.

News
    
News

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, CALT on Behalf of Shareholders

  • NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Akili, Inc. (NASDAQ:AKLI)'s sale to Virtual Therapeutics for $0.4340 per share of common stock in cash. If you are an Akili shareholder, click here to learn more about your rights and options.
    Thu, Jun. 06, 2024

STOCKHOLDER ALERT: The M&A Class Action Firm Investigates Merger and Expiring Tender Offer - AKLI and CALT

  • NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are now investigating: Akili, Inc. (NASDAQ: AKLI ), relating to a tender offer from Vital Therapeutics Corporation.
    Thu, Jun. 06, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, SGE on Behalf of Shareholders

  • NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Akili, Inc. (NASDAQ:AKLI)'s sale to Virtual Therapeutics for $0.4340 per share of common stock in cash. If you are an Akili shareholder, click here to learn more about your rights and options.
    Thu, Jun. 06, 2024

AKILI INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akili, Inc. - AKLI

  • NEW ORLEANS, LA / ACCESSWIRE / June 5, 2024 / Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
    Wed, Jun. 05, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, WIRE on Behalf of Shareholders

  • NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
    Wed, Jun. 05, 2024
SEC Filings
SEC Filings

Akili, Inc. (AKLI) - SC 13G/A

  • SEC Filings
  • 11/13/2024

Akili, Inc. (AKLI) - SC 13G/A

  • SEC Filings
  • 08/09/2024

Akili, Inc. (AKLI) - SC 13G/A

  • SEC Filings
  • 08/05/2024

Akili, Inc. (AKLI) - 15-12G

  • SEC Filings
  • 07/12/2024

Akili, Inc. (AKLI) - EFFECT

  • SEC Filings
  • 07/10/2024

Akili, Inc. (AKLI) - SC 13D/A

  • SEC Filings
  • 07/09/2024

Akili, Inc. (AKLI) - 4

  • SEC Filings
  • 07/08/2024

Akili, Inc. (AKLI) - SC 13G/A

  • SEC Filings
  • 07/05/2024

Akili, Inc. (AKLI) - SC 13D/A

  • SEC Filings
  • 07/05/2024

Akili, Inc. (AKLI) - 4

  • SEC Filings
  • 07/05/2024

Akili, Inc. (AKLI) - SC TO-T/A

  • SEC Filings
  • 07/02/2024

Akili, Inc. (AKLI) - SC 14D9/A

  • SEC Filings
  • 07/02/2024

Akili, Inc. (AKLI) - S-8 POS

  • SEC Filings
  • 07/02/2024

Akili, Inc. (AKLI) - POS AM

  • SEC Filings
  • 07/02/2024

Akili, Inc. (AKLI) - 4

  • SEC Filings
  • 07/02/2024

Akili, Inc. (AKLI) - 25-NSE

  • SEC Filings
  • 07/02/2024

Akili, Inc. (AKLI) - 4

  • SEC Filings
  • 06/11/2024

Akili, Inc. (AKLI) - SC 13G

  • SEC Filings
  • 06/10/2024

Akili, Inc. (AKLI) - SC 14D9

  • SEC Filings
  • 06/05/2024

Akili, Inc. (AKLI) - SC TO-T

  • SEC Filings
  • 06/03/2024

Akili, Inc. (AKLI) - SC 13D/A

  • SEC Filings
  • 05/31/2024

Akili, Inc. (AKLI) - SC 13D/A

  • SEC Filings
  • 05/30/2024

Akili, Inc. (AKLI) - SC14D9C

  • SEC Filings
  • 05/29/2024

Akili, Inc. (AKLI) - SC TO-C

  • SEC Filings
  • 05/29/2024

Akili, Inc. (AKLI) - 4

  • SEC Filings
  • 05/06/2024

Akili, Inc. (AKLI) - 4

  • SEC Filings
  • 03/12/2024

Akili, Inc. (AKLI) - DEFA14A

  • SEC Filings
  • 03/06/2024

Akili, Inc. (AKLI) - DEF 14A

  • SEC Filings
  • 03/06/2024

Akili, Inc. (AKLI) - ARS

  • SEC Filings
  • 03/06/2024

Akili, Inc. (AKLI) - S-8

  • SEC Filings
  • 02/29/2024

Akili, Inc. (AKLI) - PRE 14A

  • SEC Filings
  • 02/23/2024

Akili, Inc. (AKLI) - 4

  • SEC Filings
  • 02/23/2024

Akili, Inc. (AKLI) - 3

  • SEC Filings
  • 02/23/2024

Akili, Inc. (AKLI) - SC 13G

  • SEC Filings
  • 02/12/2024

Akili, Inc. (AKLI) - SC 13G/A

  • SEC Filings
  • 01/29/2024

Akili, Inc. (AKLI) - 4

  • SEC Filings
  • 12/08/2023

Akili, Inc. (AKLI) - 4

  • SEC Filings
  • 11/06/2023

Akili, Inc. (AKLI) - 4

  • SEC Filings
  • 10/13/2023

Akili, Inc. (AKLI) - SC 13D/A

  • SEC Filings
  • 10/06/2023

Akili, Inc. (AKLI) - 4

  • SEC Filings
  • 10/06/2023

Akili, Inc. (AKLI) - EFFECT

  • SEC Filings
  • 10/02/2023

Akili, Inc. (AKLI) - POS AM

  • SEC Filings
  • 09/27/2023

Akili, Inc. (AKLI) - 4

  • SEC Filings
  • 09/14/2023

Akili, Inc. (AKLI) - 424B3

  • SEC Filings
  • 09/13/2023

Akili, Inc. (AKLI) - POS AM

  • SEC Filings
  • 09/05/2023

Akili, Inc. (AKLI) - 424B3

  • SEC Filings
  • 08/10/2023

Akili, Inc. (AKLI) - 424B3

  • SEC Filings
  • 06/07/2023

Akili, Inc. (AKLI) - 424B3

  • SEC Filings
  • 05/12/2023

Akili, Inc. (AKLI) - 424B3

  • SEC Filings
  • 05/11/2023

Akili, Inc. (AKLI) - 424B3

  • SEC Filings
  • 05/04/2023

Akili, Inc. (AKLI) - 4

  • SEC Filings
  • 05/04/2023

Akili, Inc. (AKLI) - 424B3

  • SEC Filings
  • 05/03/2023

Akili, Inc. (AKLI) - EFFECT

  • SEC Filings
  • 03/27/2023

Akili, Inc. (AKLI) - DEFA14A

  • SEC Filings
  • 03/22/2023

Akili, Inc. (AKLI) - DEF 14A

  • SEC Filings
  • 03/22/2023

Akili, Inc. (AKLI) - ARS

  • SEC Filings
  • 03/22/2023

Akili, Inc. (AKLI) - POS AM

  • SEC Filings
  • 03/21/2023

Akili, Inc. (AKLI) - 4

  • SEC Filings
  • 03/14/2023

Akili, Inc. (AKLI) - 424B3

  • SEC Filings
  • 03/07/2023

Akili, Inc. (AKLI) - SC 13G/A

  • SEC Filings
  • 02/14/2023

Akili, Inc. (AKLI) - SC 13G/A

  • SEC Filings
  • 02/13/2023

Akili, Inc. (AKLI) - SC 13G/A

  • SEC Filings
  • 02/09/2023

Akili, Inc. (AKLI) - SC 13G/A

  • SEC Filings
  • 02/07/2023

Akili, Inc. (AKLI) - SC 13G

  • SEC Filings
  • 01/20/2023

Akili, Inc. (AKLI) - 424B3

  • SEC Filings
  • 01/12/2023

Akili, Inc. (AKLI) - 424B3

  • SEC Filings
  • 01/05/2023

Akili, Inc. (AKLI) - 3/A

  • SEC Filings
  • 12/13/2022

Akili, Inc. (AKLI) - 424B3

  • SEC Filings
  • 11/14/2022

Akili, Inc. (AKLI) - 424B3

  • SEC Filings
  • 11/10/2022

Akili, Inc. (AKLI) - 4

  • SEC Filings
  • 11/04/2022

Akili, Inc. (AKLI) - S-8

  • SEC Filings
  • 10/27/2022

Akili, Inc. (AKLI) - 3

  • SEC Filings
  • 10/27/2022

Akili, Inc. (AKLI) - EFFECT

  • SEC Filings
  • 10/18/2022

Akili, Inc. (AKLI) - 424B3

  • SEC Filings
  • 10/17/2022

Akili, Inc. (AKLI) - CORRESP

  • SEC Filings
  • 10/13/2022

Akili, Inc. (AKLI) - S-1/A

  • SEC Filings
  • 09/30/2022

Akili, Inc. (AKLI) - CORRESP

  • SEC Filings
  • 09/30/2022

Akili, Inc. (AKLI) - UPLOAD

  • SEC Filings
  • 09/27/2022

Akili, Inc. (AKLI) - S-1/A

  • SEC Filings
  • 09/12/2022

Akili, Inc. (AKLI) - CORRESP

  • SEC Filings
  • 09/12/2022

Akili, Inc. (AKLI) - UPLOAD

  • SEC Filings
  • 09/06/2022

Akili, Inc. (AKLI) - SC 13D

  • SEC Filings
  • 08/30/2022

Akili, Inc. (AKLI) - SC 13G

  • SEC Filings
  • 08/29/2022

Akili, Inc. (AKLI) - SC 13G

  • SEC Filings
  • 08/26/2022

Akili, Inc. (AKLI) - S-1

  • SEC Filings
  • 08/24/2022

Akili, Inc. (AKLI) - SC 13G/A

  • SEC Filings
  • 08/23/2022

Akili, Inc. (AKLI) - SC 13D

  • SEC Filings
  • 08/23/2022

Akili, Inc. (AKLI) - 4

  • SEC Filings
  • 08/23/2022

Akili, Inc. (AKLI) - 425

  • SEC Filings
  • 08/02/2022

Akili, Inc. (AKLI) - 425

  • SEC Filings
  • 08/01/2022

Akili, Inc. (AKLI) - SEC STAFF LETTER

  • SEC Filings
  • 07/25/2022

Akili, Inc. (AKLI) - EFFECT

  • SEC Filings
  • 07/22/2022

Akili, Inc. (AKLI) - DEFM14A

  • SEC Filings
  • 07/21/2022

Akili, Inc. (AKLI) - 424B3

  • SEC Filings
  • 07/21/2022

Akili, Inc. (AKLI) - CORRESP

  • SEC Filings
  • 07/19/2022

Akili, Inc. (AKLI) - S-4/A

  • SEC Filings
  • 07/14/2022

Akili, Inc. (AKLI) - CORRESP

  • SEC Filings
  • 07/14/2022

Akili, Inc. (AKLI) - 425

  • SEC Filings
  • 07/11/2022

Akili, Inc. (AKLI) - UPLOAD

  • SEC Filings
  • 06/30/2022

Akili, Inc. (AKLI) - S-4/A

  • SEC Filings
  • 06/27/2022

Akili, Inc. (AKLI) - CORRESP

  • SEC Filings
  • 06/27/2022

Akili, Inc. (AKLI) - UPLOAD

  • SEC Filings
  • 06/17/2022

Akili, Inc. (AKLI) - S-4/A

  • SEC Filings
  • 06/10/2022

Akili, Inc. (AKLI) - CORRESP

  • SEC Filings
  • 06/10/2022

Akili, Inc. (AKLI) - UPLOAD

  • SEC Filings
  • 05/25/2022

Akili, Inc. (AKLI) - S-4/A

  • SEC Filings
  • 05/12/2022

Akili, Inc. (AKLI) - CORRESP

  • SEC Filings
  • 05/12/2022

Akili, Inc. (AKLI) - 425

  • SEC Filings
  • 04/28/2022

Akili, Inc. (AKLI) - UPLOAD

  • SEC Filings
  • 04/21/2022

Akili, Inc. (AKLI) - SEC STAFF LETTER

  • SEC Filings
  • 04/14/2022

Akili, Inc. (AKLI) - 425

  • SEC Filings
  • 04/12/2022

Akili, Inc. (AKLI) - S-4/A

  • SEC Filings
  • 04/04/2022

Akili, Inc. (AKLI) - CORRESP

  • SEC Filings
  • 04/04/2022

Akili, Inc. (AKLI) - 425

  • SEC Filings
  • 04/04/2022

Akili, Inc. (AKLI) - 425

  • SEC Filings
  • 03/17/2022

Akili, Inc. (AKLI) - 425

  • SEC Filings
  • 03/11/2022

Akili, Inc. (AKLI) - 425

  • SEC Filings
  • 03/09/2022

Akili, Inc. (AKLI) - 425

  • SEC Filings
  • 03/08/2022

Akili, Inc. (AKLI) - 425

  • SEC Filings
  • 03/07/2022

Akili, Inc. (AKLI) - 425

  • SEC Filings
  • 03/02/2022

Akili, Inc. (AKLI) - 425

  • SEC Filings
  • 02/18/2022

Akili, Inc. (AKLI) - 425

  • SEC Filings
  • 02/17/2022

Akili, Inc. (AKLI) - SC 13G

  • SEC Filings
  • 02/15/2022

Akili, Inc. (AKLI) - S-4

  • SEC Filings
  • 02/14/2022

Akili, Inc. (AKLI) - 425

  • SEC Filings
  • 02/14/2022

Akili, Inc. (AKLI) - SC 13G

  • SEC Filings
  • 02/09/2022

Akili, Inc. (AKLI) - SC 13G

  • SEC Filings
  • 02/07/2022

Akili, Inc. (AKLI) - 425

  • SEC Filings
  • 01/28/2022

Akili, Inc. (AKLI) - 425

  • SEC Filings
  • 01/27/2022

Akili, Inc. (AKLI) - 425

  • SEC Filings
  • 01/26/2022

Akili, Inc. (AKLI) - SC 13G/A

  • SEC Filings
  • 01/25/2022

Akili, Inc. (AKLI) - 4

  • SEC Filings
  • 08/16/2021

Akili, Inc. (AKLI) - SC 13G

  • SEC Filings
  • 07/12/2021

Akili, Inc. (AKLI) - SC 13G

  • SEC Filings
  • 07/07/2021

Akili, Inc. (AKLI) - 4

  • SEC Filings
  • 07/07/2021

Akili, Inc. (AKLI) - 424B4

  • SEC Filings
  • 07/01/2021

Akili, Inc. (AKLI) - S-1MEF

  • SEC Filings
  • 06/30/2021

Akili, Inc. (AKLI) - EFFECT

  • SEC Filings
  • 06/29/2021

Akili, Inc. (AKLI) - CERT

  • SEC Filings
  • 06/29/2021

Akili, Inc. (AKLI) - 8-A12B

  • SEC Filings
  • 06/29/2021

Akili, Inc. (AKLI) - S-1/A

  • SEC Filings
  • 06/25/2021

Akili, Inc. (AKLI) - CORRESP

  • SEC Filings
  • 06/25/2021

Akili, Inc. (AKLI) - UPLOAD

  • SEC Filings
  • 06/15/2021

Akili, Inc. (AKLI) - S-1/A

  • SEC Filings
  • 06/09/2021

Akili, Inc. (AKLI) - S-1

  • SEC Filings
  • 06/02/2021

Akili, Inc. (AKLI) - DRS

  • SEC Filings
  • 04/21/2021
Press Releases
StockPrice Release
More Headlines
News

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 31, 2024, for Shares of Akili, Inc. – AKLI

  • NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Akili , Inc. ( NASDAQ: AKLI ), relating to a tender offer from Vital Therapeutics Corporation. Under the terms of the agreement, Vital Therapeutics Corporation will acquire all the outstanding shares of Akili common stock for $0.4340 cash per share.
  • 06/05/2024

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 31, 2024, for Shares of Akili, Inc. - AKLI

  • NEW YORK , June 4, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Akili, Inc. (NASDAQ: AKLI), relating to a tender offer from Vital Therapeutics Corporation.
  • 06/04/2024

AKLI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akili, Inc. Is Fair to Shareholders

  • NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Akili, Inc. (NASDAQ: AKLI) to Virtual Therapeutics for $0.4340 per share of common stock in cash is fair to Akili shareholders. Halper Sadeh encourages Akili shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Akil.
  • 06/03/2024

Shareholder Alert: Ademi LLP investigates whether Akili, Inc. has obtained a Fair Price for its Public Shareholders

  • MILWAUKEE , May 29, 2024 /PRNewswire/ -- Ademi LLP is investigating Akili (Nasdaq: AKLI) for possible breaches of fiduciary duty and other violations of law in its transaction with Virtual Therapeutics. Click here to learn how to join the https://www.ademilaw.com/case/akili-inc or call Guri Ademi toll-free at 866-264-3995.
  • 05/29/2024

PureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading Digital Health Company

  • BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Akili Interactive and Virtual Therapeutics Enter Into Definitive Merger Agreement to Establish Leading Digital Health Company.
  • 05/29/2024

Virtual Therapeutics, Akili Interactive Enter Into Definitive Merger Agreement to Establish Leading Digital Health Company

  • KIRKLAND, Wash. & BOSTON--(BUSINESS WIRE)--Virtual Therapeutics, a company focused on improving mental health at scale using engaging, immersive games, and Akili, Inc. (Nasdaq: AKLI), a leading digital therapeutics company, today announced the signing of a definitive merger agreement to form a diversified, leading digital health company. Under the terms of the agreement, Akili shareholders will receive $0.4340 per share of common stock in cash. The per share purchase price represents an approxi.
  • 05/29/2024

Akili Reports First Quarter 2024 Financial Results and Provides Business Update

  • BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter ended March 31, 2024 and provided an update on business progress. As announced in late April 2024, the Company's board of directors has initiated a process that is currently ongoing to evaluate potential strategic alternatives to maximize shareholder value. “We are working expeditiously with our board of directors and our external advisors and look forwar.
  • 05/14/2024

Why Is Akili (AKLI) Stock Up 68% Today?

  • Akili (NASDAQ: AKLI ) stock is rocketing higher on Tuesday after the digital medicine company provided investors with a positive corporate update. According to this update, Shionogi has canceled and forgiven $5 million in debt that Akili owed it.
  • 04/30/2024

Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

  • BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter and full year ended December 31, 2023, and provided an update on business progress. “We continue to see clear demand for our innovative, digital therapeutics, particularly amidst the ongoing mental health crisis and increasing awareness of adult ADHD prevalence,” said Matt Franklin, Chief Executive Officer at Akili. “Our mid-year shift to a leaner, custom.
  • 02/29/2024

Should You Sell Your Penny Stocks? 3 Tips for When to Sell

  • Investing in penny stocks offers a unique opportunity for investors looking to expand their portfolios with potentially high-reward options. Recognized for their affordability, these stocks allow individuals to purchase shares in emerging companies without a significant financial outlay.
  • 02/27/2024

PureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx ® for Pediatric ADHD Patients in Japan

  • BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that its Founded Entity Akili, Inc. (Nasdaq: AKLI) announced that its Japanese partner Shionogi & Co. Ltd has submitted Akili's digital therapeutic SDT-001 for marketing approval with the Ministry of Health, Labor, and Welfare. SDT-001 is the Japanese, localized version of A.
  • 02/27/2024

Why Is Akili (AKLI) Stock Up 110% Today?

  • A little known penny stock is turning heads on Wall Street today as it surges to impressive heights. Digital health company Akili Interactive Labs (NASDAQ: AKLI ) stock is soaring after reporting a positive trial update.
  • 02/26/2024

Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx® for Pediatric ADHD Patients in Japan

  • BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced that its Japanese partner Shionogi & Co. Ltd has submitted Akili's digital therapeutic SDT-001 for marketing approval with the Ministry of Health, Labor, and Welfare. SDT-001 is the Japanese, localized version of Akili's AKL-T01 (marketed as EndeavorRx® in the United States), which has previously been authorized by the U.S. Food and Drug Administration (FDA) as the world's first prescrip.
  • 02/26/2024

Akili Announces Release Date for Fourth Quarter and Full Year 2023 Financial Results, Provides Investor Communications and Board and Corporate Governance Updates

  • BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today provided several corporate updates, including that it plans to report fourth quarter and full year 2023 financial results and a business update via press release on Thursday, February 29, 2024 after the market closes. The company will not be hosting an earnings conference call for this release. Akili is also providing the following updates: Upcoming Conference Participation Akili CEO Matt Franklin wil.
  • 02/21/2024

Akili, Inc. (AKLI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

  • Akili, Inc. (AKLI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
  • 01/15/2024

Akili, Inc. (AKLI) Upgraded to Buy: Here's What You Should Know

  • Akili, Inc. (AKLI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
  • 12/21/2023

Akili, Inc. (AKLI) Q3 2023 Earnings Call Transcript

  • Akili, Inc. (NASDAQ:AKLI ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Caty Reid - Vice President Marketing & Communications Matt Franklin - President & Chief Operating Officer Scott Kollins - Chief Medical Officer Santosh Shanbhag - Chief Financial Officer Conference Call Participants Vikram Purohit - Morgan Stanley Charles Rhyee - TD Cowen Rahul Rakhit - LifeSci Capital Operator Good afternoon, ladies and gentlemen and welcome to the Akili Interactive Labs Third Quarter 2023 Earnings Call. [Operator Instructions] This call is being recorded on Thursday, November 9, 2023.
  • 11/12/2023

Akili to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 9 at 4:30 p.m. ET

  • BOSTON--(BUSINESS WIRE)--Akili to Host Third Quarter Financial Results Conference Call on Thursday, November 9 at 4:30 p.m.
  • 10/19/2023

Employees with ADHD Aren't Reaching Their Full Potential at Work, Akili Study Finds

  • BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), the leading digital medicine company behind EndeavorOTC™, today released results from a new study examining the ways in which ADHD impacts the U.S. workforce. Akili engaged Wakefield Research to survey 500 employees with ADHD to better understand the experience of working with ADHD, as well as 500 managers to explore how prepared workplaces are to support employees with ADHD. The study found that nearly all employees with ADHD (97%) think the.
  • 10/12/2023

Akili Announces Leadership Transition

  • BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced that Eddie Martucci transitioned to the role of Board chair, and Matt Franklin has been appointed to serve as president and CEO of the company and as a member of its board of directors, effective October 5, 2023. Martucci replaces former Board chair, Chamath Palihapitiya, who has resigned from the Board, effective October 4, 2023. The leadership transition follows the company's announcement.
  • 10/06/2023

Akili Releases EndeavorOTC™ on Android™ Devices, Expanding Treatment Access for Millions of Adults with ADHD

  • BOSTON--(BUSINESS WIRE)--Akili Releases EndeavorOTC on Android™ Devices, Expanding Treatment Access for Millions of Adults with ADHD.
  • 09/21/2023

Akili Announces Business Transformation, Focusing on Non-prescription Model

  • BOSTON--(BUSINESS WIRE)--Akili plans transition to non-Rx business, increasing patient access to clinically-proven non-drug treatments and reducing reliance on intermediaries.
  • 09/13/2023

Akili, Inc. (AKLI) Q2 2023 Earnings Call Transcript

  • Akili, Inc. (NASDAQ:AKLI ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Julie DiCarlo - Senior Vice President, Communications Eddie Martucci - Chief Executive Officer Matt Franklin - President and Chief Operating Officer Santosh Shanbhag - Chief Financial Officer Scott Kollins - Chief Medical Officer Conference Call Participants Judah Frommer - Credit Suisse Gus Paul - Morgan Stanley Rahul Rakhit - LifeSci Capital Operator Good afternoon, ladies and gentlemen, and welcome to the Akili, Inc. Second Quarter 2023 Earnings Conference Call. [Operator Instructions] This call is being recorded on Thursday, August 10, 2023.
  • 08/13/2023

Akili Reports Second Quarter 2023 Financial Results and Provides Business Update

  • BOSTON--(BUSINESS WIRE)--Akili Reports Second Quarter 2023 Financial Results and Provides Business Update.
  • 08/10/2023

Akili to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 10 at 4:30 p.m. ET

  • BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will host a conference call and webcast to review its financial and operating results for the second quarter of 2023 on Thursday, August 10, 2023, at 4:30 p.m. ET. A live audio webcast of the conference call and presentation will be available at www.akiliinteractive.com under Investor Relations, Events & Presentations. An archived version of the webcast will be available on the company's website followi.
  • 07/10/2023

Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress

  • BOSTON--(BUSINESS WIRE)---- $AKLI #ADHD--Akili To Presents Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at Upcoming Scientific Meetings.
  • 05/31/2023

Why Is Akili (AKLI) Stock Up 21% Today?

  • Akili (NASDAQ: AKLI ) stock is gaining on Wednesday after the company's video game treatment showed success in reducing ADHD in adults. Akili's EndeavorRx treatment uses video games to treat patients who deal with the effects of ADHD.
  • 05/03/2023

Akili, Inc. (AKLI) Q4 2022 Earnings Call Transcript

  • Akili, Inc. (NASDAQ:AKLI ) Q4 2022 Earnings Conference Call March 7, 2023 4:30 PM ET Company Participants Julie DiCarlo - Senior Vice President of Communications Eddie Martucci - Co-Founder, CEO & Director Matthew Franklin - President & COO Scott Kollins - Chief Medical Officer Santosh Shanbhag - CFO & Treasurer Conference Call Participants Nicholas Japhet - Credit Suisse Michael Cherny - BofA Securities Rahul Rakhit - LifeSci Capital Vikram Purohit - Morgan Stanley Marie Thibault - BTIG Operator Greetings, and welcome to the Akili Fourth Quarter 2022 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.
  • 03/10/2023

5 Hot Penny Stocks Exploding After News This Week

  • Hot penny stocks with news to watch this week. The post 5 Hot Penny Stocks Exploding After News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 01/05/2023

Akili, Inc. (AKLI) Q3 2022 Earnings Call Transcript

  • Akili, Inc. (NASDAQ:AKLI ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Joshua Young - IR Walter Martucci - Co-Founder, CEO & Director Matthew Franklin - President & COO Santosh Shanbhag - CFO & Treasurer Conference Call Participants Charles Rhyee - Cowen Judah Frommer - Crédit Suisse Rahul Rakhit - LifeSci Capital Operator Greetings, and welcome to Akili's Third Quarter 2022 Conference Call. At this time, all participants are in a listen-only mode.
  • 11/13/2022

Akili: Developing Video Games To Treat Cognitive Impairments

  • Akili is developing video games as a means to treat ADHD, depression, and other conditions. The company has approval by the FDA to treat ADHD using its product EndeavorRx. It is also approved to market in "the European Economic Area."
  • 10/31/2022

Akili Completes Business Combination With Social Capital Suvretta Holdings Corp. I (DNAA)

  • Akili announced it has completed its previously announced business combination with Social Capital Suvretta Holdings Corp. I (DNAA). These are the details.
  • 08/20/2022

Akili to Present at Cowen's 42nd Annual Health Care Conference

  • BOSTON--(BUSINESS WIRE)-- #DTx--Akili Management to Present at Cowen's 42nd Annual Health Care Conference
  • 03/07/2022

DNAA Stock Alert: Chamath Palihapitiya's SPAC Preps for Akili Interactive Merger

  • DNAA stock is on the rise today after news its blank-check company, backed by Chamath Palihapitiya, is merging with Akili Interactive. The post DNAA Stock Alert: Chamath Palihapitiya's SPAC Preps for Akili Interactive Merger appeared first on InvestorPlace.
  • 01/26/2022

Chamath Palihapitiya Announces SPAC Deal For Akili: Revolutionary Digital Therapy For Mental Illness

  • A biotech focused SPAC launched by frequent SPAC sponsor Chamath Palihapitiya announced a merger deal Wednesday morning. The SPAC Deal: Palihapitiya's Social Capital Suvretta Holdings Corp I (NASDAQ: DNAA) announced a SPAC merger with Akili Interactive, valuing the company at an equity value of $1 billion.
  • 01/26/2022

2 Chamath Palihapitiya SPAC Deals Rumored: Will He Land The Year's First Deal Once Again?

  • The 2022 year has started quietly for SPACs, with no deals announced in the first five trading days of the year. Although two new SPAC rumors have popped up since the market closed on Friday and both involve a well-known name in the SPAC space.
  • 01/09/2022
Unlock
AKLI Ratings Summary
AKLI Quant Ranking